Clinical trials: Skin Tests
Lice; Head Lice
Safety, Efficacy and Preventative Effect of a Head Lice Product (X92001483) vs. Nix Creme Rinse (1% Permethrin).
To compare the safety, effectiveness, and preventive benefits of a medical device (X92001483) against Nix Cream Rinse (1% Permethrin) in people with head lice
- Trial name
- NCT07660354
- Testing
- Medical Device (X92001483)
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Oystershell NV
Dermatitis, Phototoxic
Study to Learn More About the Potential of Antifungal Cream V61-044 Containing Trolamine to Cause Irritant Reaction of the Skin to Ultra Violet Light in Healthy Human Subjects
In this study researchers want to gather information about the potential of Antifungal Cream V61-044 containing Trolamine to produce a phototoxic reaction on the skin.
- Trial name
- NCT04531527
- Testing
- Butenafine HCl 1% (BAY1896425)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Bayer
SARS-CoV 2, COVID
In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity
The COVID-19 Androgen Sensitivity Test is a non-invasive In-Vitro Diagnostic device that utilizes Next Generation Sequencing Technology (NGS).
- Conditions
- SARS-CoV 2, COVID, COVID-19, Androgenetic Alopecia
- Trial name
- NCT04368897
- Testing
- CAG length <22, CAG length >=22
- Where
- Spain
- Sponsor
- Applied Biology, Inc.
Acne
Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne
The primary objective of this study is to compare the efficacy and safety and tolerability of ACYC Gel and vehicle in the treatment of subjects with Acne Vulgaris.
- Trial name
- ACYC (NCT01701024)
- Testing
- ACYC, ACYC vehicle
- Where
- 24 sites in United States
- Volunteers
- 498 people
- Sponsor
- Bausch Health Americas, Inc.
Mucopolysaccharidosis IVA, Morquio A Syndrome
Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome
The primary objective of this study was to evaluate the safety of a 2.0 mg/kg/week and a 4.0 mg/kg/week of BMN 110 in patients with Morquio A syndrome for up to 196 weeks.
- Conditions
- Mucopolysaccharidosis IVA, Morquio A Syndrome, MPS IVA
- Trial name
- NCT01609062
- Testing
- BMN 110
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 25 people
- Sponsor
- BioMarin Pharmaceutical
Contact Dermatitis
Clinical Evaluation of Lyral® Dose Response Study
The purpose of this study is to determine optimal allergen dose as the lowest concentration eliciting positive reactions in 70-90% of subjects.
- Trial name
- NCT02028182
- Testing
- Lyral®
- Where
- Denmark
- Volunteers
- 22 people
- Sponsor
- Allerderm